Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions

Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions

Dabigatran, rivaroxaban, apixaban, and edoxaban are direct oral anticoagulants (DOACs) that are increasingly used worldwide. Taking into account their widespread use for the prevention of thromboembolism in cardiology, neurology, orthopedics, and coronavirus disease 2019 (COVID 19) as well as their...

Full description

Bibliographic Details
Main Authors: Natalia A. Shnayder, Marina M. Petrova, Pavel A. Shesternya, Alina V. Savinova, Elena N. Bochanova, Olga V. Zimnitskaya, Elena A. Pozhilenkova, Regina F. Nasyrova
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Biomedicines
Subjects:
pharmacokinetics
pharmacogenetics
dabigatran
rivaroxaban
apixaban
edoxaban
Online Access:https://www.mdpi.com/2227-9059/9/5/451

Internet

https://www.mdpi.com/2227-9059/9/5/451

Similar Items